Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
HMGN5 encodes a nuclear protein with similarities to the high mobility group proteins, HMG14 and HMG17, which suggests that this protein may function as a nucleosomal binding and transcriptional activating protein. Additionally we are shipping HMGN5 Proteins (5) and many more products for this protein.
Showing 10 out of 34 products:
Human Polyclonal HMGN5 Primary Antibody for ICC, IF - ABIN4340715
Malicet, Rochman, Postnikov, Bustin: Distinct properties of human HMGN5 reveal a rapidly evolving but functionally conserved nucleosome binding protein. in Molecular and cellular biology 2011
Show all 2 Pubmed References
NSBP1 was highly expressed in NSCLC cells. NSBP1 siRNA knockdown suppressed NSCLC cell proliferation and invasion. miR326 has a putative binding site in the NSBP1 3'UTR (show UTS2R Antibodies). NSBP1 overexpression abolished miR326 inhibition of cyclin B1 (show CCNB1 Antibodies) and MMP9 (show MMP9 Antibodies) expression.
HMGN5 overexpression is correlated with advanced pathological grade and poorer prognosis in meningiomas
Decreased miR (show MLXIP Antibodies)-340 expression may contribute to the development and progression of prostate cancer through a mechanism that involves HMGN5.
Our data first time identified miR (show MLXIP Antibodies)-186 as the upstream regulator of NSBP1
High HMGN5 expression is associated with urothelial bladder cancer.
HMGN5 is an oncogene (show RAB1A Antibodies) and plays an important role in prostate cancer tumorigenesis and progression. the level of HMGN5 may be used as a biomarker to predict the patients that would benefit from gemcitabine treatment.
HMGN5 plays an oncogenic role in human breast cancer by inhibiting cell proliferation and invasion, and activating apoptosis, which could be exploited as a target for therapy in human breast cancer.
HMGN5 knockdown sensitizes prostate cancer cells to ionizing radiation
HMGN5 plays oncogenic role in osteosarcoma by promoting cell proliferation and invasion, and could be exploited as a target for therapy in osteosarcoma.
HMGN5 is a critical factor in the development of chemoresistance through regulating autophagy, and it offers a novel target for improving osteosarcoma therapy.
Hmgn5 might act downstream of Hoxa10 (show HOXA10 Antibodies) to regulate the expression of Cox-2 (show COX2 Antibodies), Vegf (show VEGFA Antibodies) and Mmp2 (show MMP2 Antibodies).
Mice overexpressing HMGN5, either globally or only in the heart, are normal at birth but develop hypertrophic heart with large cardiomyoctyes, deformed nuclei and disrupted lamina, and die of cardiac malfunction.
HMGN5 overexpression induces neurite outgrowth.
functional loss of HMGN5 leads to changes in transcription of Gpx6 (show GPX7 Antibodies) and Hk1 (show HK1 Antibodies) that alter glutathione metabolism.
Phenotypic analysis of Hmgn1 (show HMGN1 Antibodies)(tm1/tm1 (show TPM2 Antibodies)), Hmgn3 (show HMGN3 Antibodies)(tm1/tm1 (show TPM2 Antibodies)), and Hmgn5(tm1/tm1 (show TPM2 Antibodies)) mice and their wild type littermates with a battery of standardized tests uncovered variant-specific abnormalities.
Downregulation of NSBP1 reduced the cancer growth rate, whereas tumourigenicity was not influenced.
NSBP1 is an architectural protein that binds preferentially to euchromatin and modulates the fidelity of the cellular transcription profile by counteracting the chromatin-condensing activity of linker histones.
This gene encodes a nuclear protein with similarities to the high mobility group proteins, HMG14 and HMG17, which suggests that this protein may function as a nucleosomal binding and transcriptional activating protein.
high mobility group nucleosome-binding domain-containing protein 5
, high-mobility group nucleosome binding domain 5
, nucleosomal binding protein 1
, nucleosome-binding protein 1
, high-mobility group nucleosome binding domain 5-like 1
, nucleosome binding protein 1
, nucleosome binding protein 45